OXT and diabetes mellitus: Previous reports showed that intracerebroventricular administration of oxytocin or oral administration of rare sugar D-allulose (GLP-1 releaser) at LP onset, but not DP onset, ameliorated arrhythmic overeating, obesity, and diabetes in DIO mice or rats (21, 61).